Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03679884 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep
A Phase 3 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 804
- Enrollment target
NCT03679884 is a Phase 3 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 804 participants.
The verdict
NCT03679884, a Phase 3 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 804 participants
- Enrollment target
Study Summary
Study to assess the long term safety and tolerability of daridorexant in adult and elderly subjects suffering from difficulties to sleep
Interventions
- DRUG Placebo
- DRUG Daridorexant 50 mg
- DRUG Daridorexant 25 mg
- DRUG Daridorexant 10 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 804 participants |
| Start Date | 2018-10-09 |
| Est. Completion | 2021-02-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03679884
The ClinicalTrials.gov registry entry for NCT03679884 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 804 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT03679884 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03679884 about?
NCT03679884 is a clinical study titled "Study to Assess the Long Term Safety and Tolerability of ACT-541468 (Daridorexant) in Adult and Elderly Subjects Suffering From Difficulties to Sleep". Study to assess the long term safety and tolerability of daridorexant in adult and elderly subjects suffering from difficulties to sleep
What is the current status of trial NCT03679884?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 804 participants. The study started on 2018-10-09. Estimated completion is 2021-02-22.
What interventions are being tested in trial NCT03679884?
The interventions under investigation include: Placebo (DRUG), Daridorexant 50 mg (DRUG), Daridorexant 25 mg (DRUG), Daridorexant 10 mg (DRUG).
Who is sponsoring clinical trial NCT03679884?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.